A. S. Polyakova
Research Subjects
A. S. Polyakova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Andrey Borisovich Bogdanov
Botkin Moscow Multidisciplinary Scientific and Clinical Centre; Russian Medical Academy of Continuous Professional Education
2 shared publications - E. I. Veliev
S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow Healthcare Department; Department of Urology and Surgical Andrology, Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia
2 shared publications - Vladimir K. Tatochenko
National Medical Research Center of Children’s Health
2 shared publications - A.A. Tkacheva Tkacheva1 shared publication
- Aleksandr Aleksandrovich Baranov
Russian Scientific Center of Surgery named after B. V. Petrovsky; I. M. Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Andrey Tomilov
Moscow Urological Center, S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow Healthcare Department
1 shared publication
Latest Publications
- Open Access
- 1 December 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (4) , 104-111
Effectiveness of pembrolizumab in therapy of sarcomatoid variant of metastatic urothelial carcinoma. Clinical case
Sarcomatoid variant of urothelial carcinoma is a rare histological subtype: it is diagnosed in 0.1–0.3 % of all neoplasms of the bladder. The standard 1st line therapy for all types of advanced urothelial carcinoma is chemotherapy which does not necessarily allow to achieve the best or complete responses, especially in the presence of sarcomatoid differentiation. High programmed cell death-ligand 1 (PD-L1) expression in this morphological subtype allows to assume better results of immunotherapy compared to chemotherapy. However, a large number of observations is necessary to confirm this hypothesis and suggest pembrolizumab immunotherapy as a standard 1st line therapy for metastatic urothelial carcinoma with sarcomatoid differentiation.
- 1 December 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (4) , 104-111
Open AccessEffectiveness of pembrolizumab in therapy of sarcomatoid variant of metastatic urothelial carcinoma. Clinical case
Sarcomatoid variant of urothelial carcinoma is a rare histological subtype: it is diagnosed in 0.1–0.3 % of all neoplasms of the bladder. The standard 1st line therapy for all types of advanced urothelial carcinoma is chemotherapy which does not necessarily allow to achieve the best or complete responses, especially in the presence of sarcomatoid differentiation. High programmed cell death-ligand 1 (PD-L1) expression in this morphological subtype allows to assume better results of immunotherapy compared to chemotherapy. However, a large number of observations is necessary to confirm this hypothesis and suggest pembrolizumab immunotherapy as a standard 1st line therapy for metastatic urothelial carcinoma with sarcomatoid differentiation.
- Open Access
- 5 March 2024
- Published by Rostov State Medical University in Urology Herald
- Vol. 12 (1) , 91-97
Artificial urinary sphincter implantation: outcomes evaluation in a cohort of patients beyond a ten-year follow-up
Introduction. Implantation of an artificial urinary sphincter (AUS) is the main treatment method for patients with intrinsic sphincteric deficiency. There are few studies investigating the effectiveness, safety, and impact on the quality of life of the AUS implantation beyond a ten-year follow-up.Objective. To evaluate the outcomes of the AUS implantation in terms of safety, efficacy, and impact on quality of life in a group of patients beyond a ten-year follow-up.Materials & methods. From 2004 to 2023, AUS were implanted in 62 patients with severe stress urinary incontinence, of whom 14 had a follow-up period of more than 10 years. Urine loss is estimated using bladder diary. The use of ≤1 pad per day (“social continence”) was considered as cure. The quality of life was assessed using the IPSS-QoL scale and the ICIQ-UI SF questionnaire. Complications are described according to the Clavien-Dindo classification.Results. The median age of the patient at the time of implantation was 66 [63; 68] years. The causes of severe stress urinary incontinence were the following interventions: radical prostatectomy — 11 patients, radical cystectomy — two patients, transurethral resection of the prostate — one patient. The median time after the intervention that caused urinary incontinence was 20 [15; 26] months. The effectiveness of implantation was evaluated in 11 patients, three patients had complications preventing the use of the AUS. Median follow-up was 137 [124; 160] months. There was a statistically significant decrease in the median urine loss from 700,0 [600; 800] to 12,5 [1; 60] ml. There was also a significant reduction in the use of pads per day from 7 [7; 8] to 1 [0; 2]. Five patients did not use pads. Seven patients met the criterion of cure. Median IPSS-QoL scores decreased from 4 [4; 5] to 2 [1; 2]. After treatment, the score of the ICIQ-UI SF questionnaire was 8 [6; 10]. Complications superior to Clavien-Dindo II were noted in 8 of 14 patients. Eight patients underwent 15 revisions, six of them repeated. The AUS was partially or completely removed in six patients.Conclusions. Over a ten-year follow-up period, a significant number of patients developed complications, including those requiring removal or replacement of the AUS or its components, and therefore patients with an AUS require regular long-term follow-up. Despite a significant proportion of patients who required an AUS revision, implantation leads to a statistically significant reduction in urine loss and an improvement in the quality of life.
- 5 March 2024
- Published by Rostov State Medical University in Urology Herald
- Vol. 12 (1) , 91-97
Open AccessArtificial urinary sphincter implantation: outcomes evaluation in a cohort of patients beyond a ten-year follow-up
Introduction. Implantation of an artificial urinary sphincter (AUS) is the main treatment method for patients with intrinsic sphincteric deficiency. There are few studies investigating the effectiveness, safety, and impact on the quality of life of the AUS implantation beyond a ten-year follow-up.Objective. To evaluate the outcomes of the AUS implantation in terms of safety, efficacy, and impact on quality of life in a group of patients beyond a ten-year follow-up.Materials & methods. From 2004 to 2023, AUS were implanted in 62 patients with severe stress urinary incontinence, of whom 14 had a follow-up period of more than 10 years. Urine loss is estimated using bladder diary. The use of ≤1 pad per day (“social continence”) was considered as cure. The quality of life was assessed using the IPSS-QoL scale and the ICIQ-UI SF questionnaire. Complications are described according to the Clavien-Dindo classification.Results. The median age of the patient at the time of implantation was 66 [63; 68] years. The causes of severe stress urinary incontinence were the following interventions: radical prostatectomy — 11 patients, radical cystectomy — two patients, transurethral resection of the prostate — one patient. The median time after the intervention that caused urinary incontinence was 20 [15; 26] months. The effectiveness of implantation was evaluated in 11 patients, three patients had complications preventing the use of the AUS. Median follow-up was 137 [124; 160] months. There was a statistically significant decrease in the median urine loss from 700,0 [600; 800] to 12,5 [1; 60] ml. There was also a significant reduction in the use of pads per day from 7 [7; 8] to 1 [0; 2]. Five patients did not use pads. Seven patients met the criterion of cure. Median IPSS-QoL scores decreased from 4 [4; 5] to 2 [1; 2]. After treatment, the score of the ICIQ-UI SF questionnaire was 8 [6; 10]. Complications superior to Clavien-Dindo II were noted in 8 of 14 patients. Eight patients underwent 15 revisions, six of them repeated. The AUS was partially or completely removed in six patients.Conclusions. Over a ten-year follow-up period, a significant number of patients developed complications, including those requiring removal or replacement of the AUS or its components, and therefore patients with an AUS require regular long-term follow-up. Despite a significant proportion of patients who required an AUS revision, implantation leads to a statistically significant reduction in urine loss and an improvement in the quality of life.
- Open Access
- 17 July 2023
- Published by Rostov State Medical University in Urology Herald
- Vol. 11 (2) , 5-17
Static MRI for diagnosis of bulbous urethral strictures and assessment of spongiofibrosis grade
Introduction. Insufficient sensitivity and specificity of existing methods for diagnosing urethral stricture require more accurate methods, which may include magnetic resonance imaging (MRI).Objective. To study the possibilities of MRI to assess the extent of bulbous urethral stricture and spongiofibrosis grade.Materials & methods. The study included six men with bulbous urethral stricture, who underwent non-transecting anastomotic urethroplasty via ventral approach. Before surgery, all patients underwent retrograde urethrography according to the standard method and urethral MRI according to their own method, and their data were compared with intraoperative parameters.Results. The length of the stricture according to retrograde urethrography averaged 11.5 ± 6.3 mm, MRI — 17.8 ± 10.9 mm, intraoperative measurement — 16.7 ± 9.1 mm. There was a significant difference between the mean length of the stricture according to retrograde urethrography and the mean length according to intraoperative data (p = 0.028). There was no significant difference between the mean stricture length according to MRI data and the mean stricture length according to intraoperative data (p = 0.085). The length of spongiofibrosis according to MRI was 15.8 ± 13.6 mm on average, and 16.7 ± 12.9 mm according to intraoperative measurements. There was no significant difference between the average length of spongiofibrosis according to MRI and the average length according to intraoperative data (p = 0.092).Conclusions. MRI provides information comparable to intraoperative data on the extent of urethral stricture, location, and spongiofibrosis grade.
- 17 July 2023
- Published by Rostov State Medical University in Urology Herald
- Vol. 11 (2) , 5-17
Open AccessStatic MRI for diagnosis of bulbous urethral strictures and assessment of spongiofibrosis grade
Introduction. Insufficient sensitivity and specificity of existing methods for diagnosing urethral stricture require more accurate methods, which may include magnetic resonance imaging (MRI).Objective. To study the possibilities of MRI to assess the extent of bulbous urethral stricture and spongiofibrosis grade.Materials & methods. The study included six men with bulbous urethral stricture, who underwent non-transecting anastomotic urethroplasty via ventral approach. Before surgery, all patients underwent retrograde urethrography according to the standard method and urethral MRI according to their own method, and their data were compared with intraoperative parameters.Results. The length of the stricture according to retrograde urethrography averaged 11.5 ± 6.3 mm, MRI — 17.8 ± 10.9 mm, intraoperative measurement — 16.7 ± 9.1 mm. There was a significant difference between the mean length of the stricture according to retrograde urethrography and the mean length according to intraoperative data (p = 0.028). There was no significant difference between the mean stricture length according to MRI data and the mean stricture length according to intraoperative data (p = 0.085). The length of spongiofibrosis according to MRI was 15.8 ± 13.6 mm on average, and 16.7 ± 12.9 mm according to intraoperative measurements. There was no significant difference between the average length of spongiofibrosis according to MRI and the average length according to intraoperative data (p = 0.092).Conclusions. MRI provides information comparable to intraoperative data on the extent of urethral stricture, location, and spongiofibrosis grade.
- 1 March 2021
- Published by Bionika Media in Pharmateca
- Vol. 1_2021, 68-74
Community-acquired pneumonia in children
- 1 March 2021
- Published by Bionika Media in Pharmateca
- Vol. 1_2021, 68-74
Community-acquired pneumonia in children
- Open Access
- 3 November 2015
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 12 (4) , 441
Acute Bronchiolitis in Children. Current Approaches to Diagnosis and Therapy
Статья посвящена проблеме острого бронхиолита у детей. Актуальность данной проблемы не вызывает сомнений: по самым скромным подсчетам, ежегодно во всем мире регистрируется более 150 млн случаев бронхиолита, 7–13% из которых требуют стационарного лечения, а 1–3% — госпитализации в отделение интенсивной терапии. Наиболее часто этиологическим фактором выступают вирусы — респираторно-синцитиальный (подавляющее большинство случаев — 90%), значимым агентом является риновирус, а также вирусы гриппа А и В, парагриппа, аденовирус, коронавирус, метапневмовирус и бокавирус человека. Развитие бронхиолита у детей первых двух лет жизни может обусловить целый ряд факторов. Особенно тяжело бронхиолит протекает у недоношенных, детей с бронхолегочной дисплазией и на искусственном вскармливании, а также у пациентов с врожденными пороками развития и иммунодефицитами. Специалистами профессиональной ассоциации детских врачей — Союза педиатров России — в соответствии с принципами доказательной медицины сформулированы и кратко изложены основополагающие критерии диагностики, алгоритмы терапии и дальнейшего ведения пациентов с данной патологией.
- 3 November 2015
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 12 (4) , 441
Open AccessAcute Bronchiolitis in Children. Current Approaches to Diagnosis and Therapy
Статья посвящена проблеме острого бронхиолита у детей. Актуальность данной проблемы не вызывает сомнений: по самым скромным подсчетам, ежегодно во всем мире регистрируется более 150 млн случаев бронхиолита, 7–13% из которых требуют стационарного лечения, а 1–3% — госпитализации в отделение интенсивной терапии. Наиболее часто этиологическим фактором выступают вирусы — респираторно-синцитиальный (подавляющее большинство случаев — 90%), значимым агентом является риновирус, а также вирусы гриппа А и В, парагриппа, аденовирус, коронавирус, метапневмовирус и бокавирус человека. Развитие бронхиолита у детей первых двух лет жизни может обусловить целый ряд факторов. Особенно тяжело бронхиолит протекает у недоношенных, детей с бронхолегочной дисплазией и на искусственном вскармливании, а также у пациентов с врожденными пороками развития и иммунодефицитами. Специалистами профессиональной ассоциации детских врачей — Союза педиатров России — в соответствии с принципами доказательной медицины сформулированы и кратко изложены основополагающие критерии диагностики, алгоритмы терапии и дальнейшего ведения пациентов с данной патологией.